Christian Meyer Zum Buschenfelde
Overview
Explore the profile of Christian Meyer Zum Buschenfelde including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
1248
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Borchmann P, Ferdinandus J, Schneider G, Moccia A, Greil R, Hertzberg M, et al.
Lancet
. 2024 Jul;
404(10450):341-352.
PMID: 38971175
Background: Intensified systemic chemotherapy has the highest primary cure rate for advanced-stage, classical Hodgkin lymphoma but this comes with a cost of severe and potentially life long, persisting toxicities. With...
2.
Stratmann J, Althoff F, Doebel P, Rauh J, Trummer A, Hunerliturkoglu A, et al.
Eur J Cancer
. 2024 Feb;
201:113911.
PMID: 38377774
Background: Sotorasib is a first-in-class KRAS p.G12C-inhibitor that has entered clinical trials in pretreated patients with non-small cell lung cancer (NSCLC) in 2018. First response rates were promising in the...
3.
Habringer S, Demel U, Fietz A, Lammer F, Schroers R, Hofer S, et al.
Eur J Cancer
. 2023 Nov;
196:113436.
PMID: 38008033
Background: Secondary central nervous system lymphoma (SCNSL) confers a dismal prognosis and treatment advances are constrained by the lack of prospective studies and real-world treatment evidence. Methods: Patients with SCNSL...
4.
Faehling M, Witte H, Sebastian M, Ulmer M, Satzler R, Steinestel K, et al.
Ther Adv Med Oncol
. 2022 Mar;
14:17588359221085333.
PMID: 35356258
Background: Recent clinical trials demonstrate the feasibility of neoadjuvant immuno(chemo)therapy and report high rates of pathological remission, a surrogate marker for overall survival. Patients And Methods: This is a retrospective...
5.
Hainsworth J, Daugaard G, Lesimple T, Hubner G, Greco F, Stahl M, et al.
Cancer
. 2015 Jan;
121(10):1654-61.
PMID: 25611313
Background: The objective of this study was to evaluate the efficacy of belinostat, a histone deacetylase inhibitor, when added to paclitaxel/carboplatin in the empiric first-line treatment of patients with carcinoma...
6.
Becker K, Reim D, Novotny A, Zum Buschenfelde C, Engel J, Friess H, et al.
Ann Surg
. 2012 Sep;
256(6):1002-7.
PMID: 22968067
Objective: We have developed a multifactorial histopathological prognostic score (PRSC) for patients with gastric cancer treated with neoadjuvant chemotherapy before surgery for the accurate discrimination of patient subgroups with differing...
7.
Weber G, Rosenberg R, Murphy J, Zum Buschenfelde C, Friess H
Expert Rev Anticancer Ther
. 2012 Apr;
12(4):481-94.
PMID: 22500685
This review outlines the important multimodal treatment issues associated with locally advanced rectal cancer. Changes to chemotherapy and radiation schema, as well as modern surgical approaches, have led to a...
8.
Biberacher V, Decker T, Oelsner M, Wagner M, Bogner C, Schmidt B, et al.
Haematologica
. 2011 Dec;
97(5):771-9.
PMID: 22180432
Background: In spite of potent first-line therapies for chronic lymphocytic leukemia, treatment remains palliative and all patients frequently relapse. Treatment options for these patients are more limited. BL22 is a...
9.
Reim D, Gertler R, Novotny A, Becker K, Zum Buschenfelde C, Ebert M, et al.
Ann Surg Oncol
. 2011 Dec;
19(7):2108-18.
PMID: 22130620
Background: Preoperative chemotherapy has been shown to improve outcome of patients with adenocarcinoma of the esophagogastric junction (AEG) and gastric cancer (GC), and histopathologic response has been identified as an...
10.
Zum Buschenfelde C, Herrmann K, Schuster T, Geinitz H, Langer R, Becker K, et al.
J Nucl Med
. 2011 Jul;
52(8):1189-96.
PMID: 21764790
Unlabelled: Previous studies demonstrated that chemotherapy-induced changes in tumor glucose metabolism measured with (18)F-FDG PET identify patients who benefit from preoperative chemotherapy and those who do not. The prognosis for...